Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 31,368 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose 2 Clear all
Completed Phase 4 Interventional Results available

BK Treatment Study

NCT01034176
View directory record Official record
Conditions
BK Viremia
Interventions
levofloxacin, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Worcester, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 25, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers

NCT01613040
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Moxifloxacin, RO4917838, RO4917838 placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 25, 2026, 4:40 AM EDT
Completed Phase 2 Interventional Results available

The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age

NCT02636868
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
Lucinactant delivered via investigational delivery device, nCPAP
Drug
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
26 Weeks to 32 Weeks
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 25, 2026, 4:40 AM EDT
Completed Phase 3 Interventional Results available

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

NCT00324155
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Placebo, Dacarbazine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
32
States / cities
Anaheim, California • La Verne, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Oct 25, 2026, 4:40 AM EDT
Completed Phase 3 Interventional Results available

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

NCT04460326
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
Insulin glargine, NovoLog, Insulin Fiasp, Standard carbohydrate diet
Drug · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 25, 2026, 4:40 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

NCT02605915
View directory record Official record
Conditions
HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer, Locally Advanced or Early Breast Cancer
Interventions
Atezolizumab, Carboplatin, Docetaxel, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Joliet, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 25, 2026, 4:40 AM EDT
Recruiting Phase 2 Interventional

Palbociclib and Pembrolizumab In Central Nervous System Metastases

NCT02896335
View directory record Official record
Conditions
Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases
Interventions
Palbociclib, Pembrolizumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 25, 2026, 4:40 AM EDT
Terminated Phase 1 Interventional

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma

NCT01106235
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
therapeutic autologous lymphocytes, aldesleukin, cyclophosphamide, biopsy
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 21, 2011 · Synced Oct 25, 2026, 4:40 AM EDT
Completed Not applicable Interventional

A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs

NCT00002308
View directory record Official record
Conditions
HIV Infections
Interventions
Stavudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 25, 2026, 4:40 AM EDT
Withdrawn Phase 2 Interventional

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

NCT05209308
View directory record Official record
Conditions
CLL
Interventions
Zandelisib, Rituximab, Venetoclax
Drug
Lead sponsor
MEI Pharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Boston, Massachusetts • Stony Brook, New York • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 25, 2026, 4:40 AM EDT
Terminated Phase 1 Interventional

Dose Escalation Trial of Intrasite Vancomycin Pharmacokinetics

NCT01764750
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Intrasite Vancomycin, IV Vancomycin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 25, 2026, 4:40 AM EDT
Active, not recruiting Phase 1 Interventional

Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)

NCT04184050
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
Interventions
MK-4002
Drug
Lead sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
8
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 25, 2026, 4:40 AM EDT
Recruiting Phase 2 Interventional

Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer

NCT07057791
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Cancer
Interventions
Ivonescimab 10 mg/kg, Ivonescimab 20 mg/kg
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
13
States / cities
Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 25, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

NCT06441318
View directory record Official record
Conditions
Healthy Participants
Interventions
Povorcitinib, Placebo, Moxifloxacin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 25, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects

NCT03870490
View directory record Official record
Conditions
Healthy Subjects
Interventions
VNRX-5133 + cefepime
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 25, 2026, 4:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Assessment of Fluticasone Propionate on Ocular Allergy Symptoms

NCT01817790
View directory record Official record
Conditions
Allergic Rhinitis, Seasonal Allergic Rhinitis
Interventions
Fluticasone propionate, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
626 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 25, 2026, 4:40 AM EDT
Active, not recruiting Phase 3 Interventional

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Gotistobart, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
46
States / cities
Dothan, Alabama • Russellville, Arkansas • Cerritos, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 25, 2026, 4:40 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

NCT03719326
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Ovarian Cancer
Interventions
Etrumadenant, IPI-549, Pegylated liposomal doxorubicin (PLD), nanoparticle albumin-bound paclitaxel (NP)
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
20
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 25, 2026, 4:40 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Acute Effect of Lorazepam on Brain Activity Measured by Magnetoencephalograpy (MEG) and Electroencephalography (EEG)

NCT01272778
View directory record Official record
Conditions
Healthy Subjects
Interventions
Lorazepam, Placebo
Drug
Lead sponsor
Orasi Medical, Inc.
Industry
Eligibility
18 Years to 35 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Elk Grove Village, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Oct 25, 2026, 4:40 AM EDT
Recruiting Phase 2 Interventional

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

NCT06115135
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions
Venetoclax
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
West Hollywood, California • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 25, 2026, 4:40 AM EDT
Completed No phase listed Observational

Kidney Dysfunction in Children and Young Adults Who Have Received Methotrexate for Acute Lymphoblastic Leukemia

NCT00993135
View directory record Official record
Conditions
Leukemia, Renal Toxicity
Interventions
methotrexate, medical chart review, assessment of therapy complications
Drug · Other · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 25, 2026, 4:40 AM EDT
Completed Phase 2 Interventional Results available

A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)

NCT02535715
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ORMD-0801 capsules- 2x8mg, ORMD-0801 capsules- 3x8mg, ORMD-0801 capsules- 1x16mg
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 25, 2026, 4:40 AM EDT
Completed Phase 4 Interventional

A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia

NCT00455715
View directory record Official record
Conditions
Schizophrenia
Interventions
Sildenafil
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Oct 25, 2026, 4:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Trial Comparing Split-Dose Miralax With Amitiza Pretreatment Versus Dulcolax Pretreatment Versus Golytely for Bowel Cleansing Prior to Colonoscopy

NCT00953017
View directory record Official record
Conditions
Colonoscopy
Interventions
Miralax (PEG 3350), Amitiza (Lubiprostone), Dulcolax (Bisacodyl), Golytely (polyethylene glycol)
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2012 · Synced Oct 25, 2026, 4:40 AM EDT